Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Immugenia Logo
Immugenia Growth Score
80
CB Rank
393837
Heat Score
27
Immugenia is an early-stage immuno-oncology company.
Founded
obfuscation
PrivatePre-Seed Sherbrooke, Quebec, Canada1-10 immugenia.com/
Biotechnology
Oncology
Therapeutics
Overview

Immugenia
Growth Score
80
Heat Score
27

Growth Score80
-10 pts
in past quarter
Heat Score 27
-18 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Immugenia

CB Rank
393837
Immugenia is an early-stage immuno-oncology company.
Founded
obfuscation
PrivatePre-Seed Sherbrooke, Quebec, Canada1-10 immugenia.com/
Biotechnology
Oncology
Therapeutics

Funding Rounds

Pre-Seed
OBF
in
obfuscation

Details

Legal Name Immugenia Inc.
Operating Status Active
Company Type For Profit
About the Company
Immugenia is an early-stage immuno-oncology company developing a novel approach to CAR therapy by engineering hematopoietic stem cells to treat cancer and prevent relapses.
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

CAR-HSC Therapy for Pre-B Acute Lymphoblastic Leukemia (CD22)
A CAR therapy modifying hematopoietic stem cells to treat pre-B acute lymphoblastic leukemia by targeting CD22 antigen.
CAR-HSC Therapy for Rhabdomyosarcoma (B7-H3)
A CAR therapy using modified hematopoietic stem cells targeting B7-H3 antigen to treat rhabdomyosarcoma, a pediatric soft tissue sarcoma.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Pre Seed Round - Immugenia Logo
Pre Seed Round - Immugenia
3
obfuscation
Sherbrooke InnopolePre-Seed
obfuscation
Pre Seed Round - Immugenia Logo
Pre Seed Round - Immugenia
3
obfuscation
Sherbrooke InnopolePre-Seed
obfuscation
Pre Seed Round - Immugenia Logo
Pre Seed Round - Immugenia
3
obfuscation
Sherbrooke InnopolePre-Seed
obfuscation
Pre Seed Round - Immugenia Logo
Pre Seed Round - Immugenia
3
obfuscation
Sherbrooke InnopolePre-Seed
obfuscation
Pre Seed Round - Immugenia Logo
Pre Seed Round - Immugenia
3
obfuscation
Sherbrooke InnopolePre-Seed

Funding Rounds

Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Pre Seed Round - Immugenia Logo
Pre Seed Round - Immugenia
3
obfuscation
Sherbrooke InnopolePre-Seed
obfuscation
Pre Seed Round - Immugenia Logo
Pre Seed Round - Immugenia
3
obfuscation
Sherbrooke InnopolePre-Seed
obfuscation
Pre Seed Round - Immugenia Logo
Pre Seed Round - Immugenia
3
obfuscation
Sherbrooke InnopolePre-Seed
obfuscation
Pre Seed Round - Immugenia Logo
Pre Seed Round - Immugenia
3
obfuscation
Sherbrooke InnopolePre-Seed
obfuscation
Pre Seed Round - Immugenia Logo
Pre Seed Round - Immugenia
3
obfuscation
Sherbrooke InnopolePre-Seed

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 1-10
News
Technology
View Tech Report

Active Website Tech Count

9Immugenia is actively using 9 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible, Viewport Meta, and  Apple Mobile Web Clips Icon.

Total IP

1Immugenia has 1 registered trademark in the 'Scientific and technological services' class, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Immugenia's headquarters? Immugenia is located in Sherbrooke, Quebec, Canada.Who invested in Immugenia? Immugenia has 3 investors including Sherbrooke Innopole and  ACET Capital.When was the last funding round for Immugenia? Immugenia closed its last funding round on
obfuscation
from a Pre-Seed round.Who are Immugenia's competitors? Alternatives and possible competitors to Immugenia may include Arcellx, Century Therapeutics, and  Sana Biotechnology.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(a422d24 1)
|